2,244 press releases in English indexed under biotech & pharma.
- Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis - Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy SAN DIEGO, Oct. 19, 2026 -- Protego...
PASADENA, Calif., October 19, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical...
WATERTOWN, Mass., Oct. 19, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The trial met all its primary and secondary endpoints.
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYUTM in Wet AMD
BOSTON & SOUTH SAN FRANCISCO, Calif., October 19, 2026--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will pr
Intracranial Objective Response Rate of 30.2% was observed in 43 evaluable patients Results to be shared in poster presentation at ESMO Congress 2026 PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Co
The development of a soft mist inhaler ( SMI ) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles A soft mist formulation may be beneficial for patients with pulmonary hypertension associated with chronic obstructive pulmonary disease ( P
SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration with Summit's Partner Akeso, with Clinical Trial Sites in the U.S. and China MIAMI, October 19, 2026 --( BU
Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 million NEW YORK & PALO ALTO, Calif., October 19, 2026--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class t